Malnutrition Severe, Antibiotic Resistance, Antibiotic Toxicity
Conditions
Brief summary
Children with severe malnutrition who are admitted sick to hospitals have a high mortality(death rate), usually because of infection. All children with severe malnutrition admitted to hospitals are treated with antibiotics(medication used to kill bacteria). However, the current antibiotics used in hospitals may not be the most effective. It is possible that the antibiotics that are currently used after initial antibiotics should be used first. No studies have been carried out to determine if the current antibiotics used for treating malnourished children who are sick and admitted in hospital are the most appropriate. The aim of this study is to find out if a changed antibiotic system for children with malnutrition is safe, reduces the risk of death and improves nutritional recovery.
Detailed description
Children with complicated severe acute malnutrition (SAM) admitted to hospital in sub-Saharan Africa have a case fatality(death rate) between 12% and more than 20%. Because children with SAM may not exhibit the usual signs of infection, WHO guidelines recommend routine antibiotics(medication used to kill bacteria). However, this is based on low quality evidence. There is evidence that because of bacterial resistance to the currently recommended first-line antibiotics (gentamicin plus ampicillin or penicillin) could be less effective than potential alternatives. Some hospitals in Africa are already increasing use of ceftriaxone as a first-line treatment. However, this is not based on any data that ceftriaxone actually improves outcomes. Of concern is that ceftriaxone use may also lead to increased antimicrobial resistance, including inducing extended spectrum beta-lactamase (ESBL) and other classes of resistance. A further area where evidence for policy is lacking is the use of metronidazole in severely malnourished children. The WHO guidelines recommend Metronidazole 7.5 mg/kg every 8 h for 7 days may be given in addition to broad-spectrum antibiotics; however, the efficacy of this treatment has not been established in clinical trials. Metronidazole is effective against anaerobic bacteria, small bowel bacterial overgrowth, Clostridium difficile colitis and also Giardia, which is common amongst children with SAM. Small cohort studies of metronidazole usage suggest there may be benefits for nutritional recovery in malnourished children. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also rarely cause liver and neurological toxicity. This multi-centre clinical trial will assess the efficacy of two interventions, ceftriaxone and metronidazole, on mortality and nutritional recovery in sick, severely malnourished children in a 2x2 factorial design. There will also be an analysis of antimicrobial resistance and an economic analysis. To extend our understanding of metronidazole and ceftriaxone pharmacokinetics, additional pharmacokinetic data for the dosing schedule used in the trial will be collected from 120 participants in a sub-study. The trial will be conducted at Kilifi County Hospital, Coast General Hospital, Mbagathi Hospital in Kenya and Mbale Regional Referral Hospital in Uganda. The trial will assess antimicrobial resistance that is carried by children in their intestines and in invasive bacterial isolates. A further sub-study will examine the relative costs of care for SAM for health facilities and for families, including antimicrobial usage will also be assessed. Clear data on the benefits, risks and costs of these antimicrobials will influence policy on case management and antimicrobial stewardship in this vulnerable population.
Interventions
DRUGCeftriaxone
Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
DRUGMetronidazole
The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials.
OTHERPlacebo
Suspension manufactured to match metronidazole
DRUGGentamicin
The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Sponsors
University of Oxford
University College, London
London School of Hygiene and Tropical Medicine
Swansea Trials Unit
Kenya Medical Research Institute
KEMRI-Wellcome Trust Collaborative Research Program
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Metronidazole and its placebo will be masked. They will both be contained in similar bottles labelled with sequential study numbers according to a prepared blocked randomisation list before the trial begins. They will also be of similar appearance. Ceftriaxone and penicillin + gentamicin will not be masked.
Intervention model description
The trial will investigate two separate antimicrobial interventions in a 2x2 factorial design randomised controlled clinical trial. A factorial design allows more than one intervention to be tested and is useful in assessing a potential package of care. Two randomisations will be made. The two interventions will be analysed separately. Ceftriaxone and metronidazole is an effective and commonly used antibiotic combination, hence major interactions that interfere with efficacy are considered unlikely. However, evidence for interaction between the two interventions will be tested.
Eligibility
Sex/Gender
ALL
Age
2 Months to 13 Years
Healthy volunteers
No
Inclusion criteria
Inclusion: * Age 2 months to 13 years inclusive * Severe malnutrition defined as: * kwashiorkor at any age or: * for children between 2 to 5 months: MUAC \<11cm or weight-for length Z score \<-3 * for children between 6 to 59 months: MUAC \<11.5cm or weight-for length Z score \<-3 * for children between 5 to 13 years: MUAC \<11.5cm or BMI-for-age Z score \<-3 * Admitted to hospital and eligible for intravenous antibiotics according to WHO guidelines * Planning to remain within the hospital catchment area and willing to come for specified visits during the 90 day follow up period * Informed consent provided by the parents/guardian Exclusion: * Known allergy or contraindication to penicillin, gentamicin, ceftriaxone or metronidazole * A specific and documented clinical indication for another class of antibiotic * Previously enrolled in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 90 days after enrolment. | Mortality is measured using source documents from medical records, verbal autopsy, or death or burial certificates in the community. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality during the first 30 days | 7 days | Mortality during the first 30 days |
| Index admission inpatient mortality | Through index hospital admission, an average of 7 days. | Mortality during the index hospitalisation, measured using inpatient records. |
| Mortality after discharge from index admission. | 90 days after enrolment | Mortality occurring after discharge from the index hospital admission is measured using inpatient medical records, verbal autopsy, or death or burial certificates in the community. |
| Grade 4 toxicity | Up to 7 days following enrolment | Grade 4 toxicity events are measured according to the Division of AIDS Tables for Grading the Severity of Adverse Events using medical records. |
| Serious adverse events | 90 days after enrolment. | Serious adverse events are measured using inpatient and outpatient medical records. |
| Tolerability - relevant side effects during the first 7 day | 7 days | Vomiting, diarrhoea, NG tube in place and convulsions during the first 7 days |
| Mortality during the first 7 days | 7 days | Mortality during the first 7 days |
| Re-admission to hospital. | From discharge from hospital to 90 days after enrolment | Re-admission to hospital defined as at least one overnight stay in a hospital or health facility are measured using inpatient records. |
| Duration of hospitalisation. | 90 days after enrolment. | Total duration of hospitalisation is measured in days using inpatient records at the start and end of each admission to hospital. |
| Duration of administration of antibiotics. | 90 days after enrolment. | Duration of administration of intravenous antibiotics measured using inpatient records. |
| Change in nutritional status | 90 days after enrolment. | Change in nutritional status is measured using mid-upper arm circumference, weight-for-length, weight-for-age and length-for-age compared to at enrollment. |
| Faecal carriage of bacteria expressing Extended Spectrum Lactamase (ESBL) | Through study completion an average of 90 days. | Faecal carriage of bacteria expressing Extended Spectrum Lactamase (ESBL) is measured using microbial culture and sensitivity testing of rectal swabs. |
| Causes of death. | 90 days after enrolment | Causes of death, as determined by an endpoint review committee. |
Countries
Kenya, Uganda
Outcome results
None listed